August 4th, 2008

Researchers around the globe are currently conducting tests in hopes of finding a daily pill that could prevent H.I.V., reports the New York Times.

While vaccines and microbicides have thus far proven ineffective in preventing H.I.V infection, AIDS experts say the prophylactic use of antiretroviral drugs, called PrEP, is the most promising form of H.I.V. prevention.

“We cannot wait for the study results to begin to prepare for the optimal use and delivery of PrEP,” said Pedro Goicochea, an investigator in a PrEP study under way in Peru and Ecuador.  “Instead, we should look ahead to consider all of the possible outcomes of these trials and make real plans for making PrEP available to those who can benefit from it, as quickly and safely as possible if it is proven effective.”

Studies in nonhuman primates have suggested that PrEP can reduce the risk of infection of a form of H.I.V.  Up to 15,000 people are expected to participate in human trials by mid-2009.